Sakura Finetech Enhances Infection Control Measures with New Vaccines

Strengthening Infection Prevention at Sakura Finetech

Sakura Finetech Japan, a provider of total solutions in pathology, is set to enhance its ongoing infection control measures by implementing a group vaccination program for seven diseases, including the newly added COVID-19 vaccine. This initiative will take place on October 28 and 29, 2025, at the company's headquarters located in Chuo Ward, Tokyo.

Comprehensive Vaccine Initiative

Since 2013, Sakura Finetech has underscored its commitment to employee health and safety by fully subsidizing vaccination costs for influenza and rubella. Over the years, this initiative has expanded to include adult pneumococcal vaccines, shingles vaccines, and most recently, COVID-19 vaccines. This year marks the introduction of the COVID-19 vaccine amid increasing infection rates and amid the request from employees for greater protection against emerging infections.

Vaccination Details

The upcoming vaccination sessions will run from 2:00 PM to 5:00 PM on both days, providing employees the chance to receive a total of five different vaccines:
1. COVID-19 Vaccine (Omicron variant JN.1 compatible)
2. MMR Vaccine (Measles, Mumps, and Rubella)
3. Influenza Vaccine
4. Adult Pneumococcal Vaccine (for those aged 60 and older)
5. Shingles Vaccine

All costs for the vaccines will be fully covered by Sakura Finetech, allowing employees to receive these vital immunizations without any financial burden.

Continuing Commitment to Health

This upcoming vaccination initiative will be the 13th time the company has organized a group vaccination, which previously saw participation from 240 employees last year. Continuing its efforts, Sakura Finetech received the